Skip to main content
. 2017 Feb 1;61(5):438–446. doi: 10.1590/2359-3997000000254

Table SM2. Distributions of genotypes and alleles frequencies in T2DM patients and controls.

Polymorphisms T2DM (n = 102) (%) Control (n = 62) (%) p
TNF-α (-308 G/A) (rs1800629) Genotypes      
GG 78 (76.5) 47 (75.8) 0.965
GA 23 (22.6) 15 (24.2)
AA 1 (0.9) 0
Alleles      
G 179 (87.8) 109 (87.9) 0.966
A 25 (12.2) 15 (12.1)
IL-6 (-174 C/G) (rs1800795) Genotypes      
CC 7 (6.8) 3 (4.8) 0.348
CG 26 (25.5) 24 (38.7)
GG 69 (67.7) 35 (56.5)
Alleles      
C 40 (19.6) 30 (24.2) 0.326
G 164 (80.4) 94 (75.8)
IL-10 (-1082 G/A) (rs1800896) Genotypes      
GG 12 (11.8) 8 (12.9) 0.864
GA 47 (46.1) 26 (41.9)
AA 43 (42.1) 28 (45.2)
Alleles      
G 71 (34.8) 42 (33.9) 0.863
A 133 (65.2) 82 (66.1)
IL-10 (-819 T/C) (rs1800871) Genotypes      
TT 13 (12.8) 7 (11.3) 0.674
TC 40 (39.2) 29 (46.8)
CC 49 (48.0) 26 (41.9)
Alleles      
T 66 (32.4) 43 (34.7) 0.665
C 138 (67.6) 81 (65.3)
IL-10 (-592 A/C) (rs1800872) Genotypes      
AA 14 (13.7) 7 (11.3) 0.742
AC 39 (38.3) 29 (46.8)
CC 49 (48.0) 26 (41.9)
Alleles      
A 67 (32.8) 43 (34.7) 0.733
C 137 (67.2) 81 (65.3)

TNF-α: tumor necrosis factor-alpha; IL-6: interleukin-6; IL-10: interleukin-10.

p < 0.05 was considered statistically significant.